Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

PD 180970

CAS 287204-45-9

C21H15Cl2FN4O  MW 429.28

Purity: >98%

Ordering Information:

Cat. No. Axon 1137

Qty1: 10 mg / €135  $176

Qty2: 50 mg / €485  $631

Qty3: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   PD180970 inhibits p210(Bcr-Abl) tyrosine kinase and induces apoptosis in Bcr-Abl-expressing leukemic cells.   References: online1, 2, 3   P La Rosée et al. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002, 62 (24), 7149-53. [online]   TS May. Gleevec: tailoring to fit. Drug Discovery Today (DDT), 2003, 8 (5), 188-189. [online]   M Huang et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002, 21(57), 8814-8816.   JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol 2008, 119, 212-217. [online]     Chemical Name: 6-(2,6-Dichloro-phenyl)-2-(4-fluoro-3-methyl-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one

PD 180970 | BCR-ABL Inhibitor | Axon Medchem | Axon 1137 | PD180970

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.